A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC).

Taofeek K. Owonikoko,Kristin Higgins,Zhengjia Chen,Chao Zhang,Rathi N. Pillai,Conor E. Steuer,Nabil F. Saba,Suchita Pakkala,Dong M. Shin,Guojing Zhang,Shuhua Wang,Mohammed S Hossain,Tyler Beardslee,Anne Engelhart,Janine Revenig,Fadlo R. Khuri,Walter J. Curran,Sagar Lonial,Edmund K. Waller,Suresh S. Ramalingam

A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC).

2019

8515Background: The combination of PD-1 and CTLA-4 inhibition has demonstrated activity in the second line therapy setting for SCLC. Radiotherapy enhanced the effectiveness of immunotherapy in NSCL...

Keywords:

Durvalumab
Phases of clinical research
Immunotherapy
Pathology
Oncology
Relapsed Small Cell Lung Cancer
Second-line therapy
Tremelimumab
Radiation therapy
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations